Synergy between PPARgamma ligands and platinum-based drugs in cancer. - Wikidata - thesis-toulmin - TriplyDB

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

http://www.wikidata.org/entity/Q36930841

about

PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention Adipocytes: impact on tumor growth and potential sites for therapeutic intervention Ubiquitin-mediated NFκB degradation pathway Chemotherapy and chemoprevention by thiazolidinediones Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy Structural and Biochemical Basis for the Binding Selectivity of Peroxisome Proliferator-activated Receptor to PGC-1 PPARγ as a Novel Therapeutic Target in Lung Cancer The non-genomic crosstalk between PPAR-gamma ligands and ERK1/2 in cancer cell lines Balance between MKK6 and MKK3 mediates p38 MAPK associated resistance to cisplatin in NSCLC Distinct genes related to drug response identified in ER positive and ER negative breast cancer cell lines Discovering anti-platelet drug combinations with an integrated model of activator-inhibitor relationships, activator-activator synergies and inhibitor-inhibitor synergies Nuclear receptor expression defines a set of prognostic biomarkers for lung cancer Carboplatin-induced gene expression changes in vitro are prognostic of survival in epithelial ovarian cancer Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma.Minireview: Familiar Faces in Unfamiliar Places: The Emerging Role of Nuclear Receptors in Lung Cancer Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.Cytotoxic effects of 15-deoxy-Δ12,14-prostaglandin J2 alone and in combination with dasatinib against uterine sarcoma in vitro.Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome.Expression profiling of nuclear receptors in the NCI60 cancer cell panel reveals receptor-drug and receptor-gene interactions.Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas.Targeting the eicosanoid pathway in non-small-cell lung cancer.Integrated genomics of ovarian xenograft tumor progression and chemotherapy response.Obesity and cancer--mechanisms underlying tumour progression and recurrence Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer Synergistic interactions between heregulin and peroxisome proliferator-activated receptor-gamma (PPARgamma) agonist in breast cancer cells.Loss of PTEN Facilitates Rosiglitazone-Mediated Enhancement of Platinum(IV) Complex LA-12-Induced Apoptosis in Colon Cancer Cells.Paracrine and endocrine effects of adipose tissue on cancer development and progression.The Key to Unlocking the Chemotherapeutic Potential of PPARγ Ligands: Having the Right Combination.Research resource: Diagnostic and therapeutic potential of nuclear receptor expression in lung cancer.Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells Chemotherapeutic drugs induce PPAR-gamma expression and show sequence-specific synergy with PPAR-gamma ligands in inhibition of non-small cell lung cancer PPARgamma and Apoptosis in Cancer.Activated PPARgamma Targets Surface and Intracellular Signals That Inhibit the Proliferation of Lung Carcinoma Cells.Clinical Use of PPARgamma Ligands in Cancer.Peroxisome proliferator-activated receptor gamma agonist pioglitazone prevents the hyperglycemia caused by phosphatidylinositol 3-kinase pathway inhibition by PX-866 without affecting antitumor activity.Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials.Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours.

P2860

Q21328702-73CFD1E0-6926-4928-AEC6-95C85C5E46C5 Q24601222-B0C27618-3E90-4A1A-819E-D0F6710F67C7 Q26830077-52DE5342-053B-45E5-97B8-742809917B48 Q26998535-64B90206-2232-498B-8688-DC15088C4230 Q27011352-442A6C24-1A95-4198-AFFA-7B4FD21886A0 Q27015257-E95E65B8-A16F-4A0D-960D-6C08C5FAB421 Q27650576-8EADE2D2-339D-4D4D-A698-F293CA284789 Q28068114-B4D05E15-0BA5-48BF-BD63-9B2993D112C4 Q28238709-8992BF5E-34AF-42A9-AB63-8AE00ED4D499 Q28478252-E1F53389-34CE-43F8-97A0-BBC6D4ACFC05 Q28481323-F6F65E12-A0F1-4042-B7A5-558FE51A7C68 Q28546587-A1A70BAE-31BF-4DF1-B3CA-8A06BD48303E Q28744237-3E837549-E026-492D-B84E-C38C1E6DB410 Q33387721-455E76D3-54B9-4431-AA7F-A118ED2B73E0 Q33580777-DC68D612-6AA0-4A8B-9BB1-99F0019549D8 Q33631471-B76C72AD-4D0A-4DD9-BBE2-5DEED34769F0 Q33637896-19A24287-87AB-49CD-B087-7D5C381198A4 Q33710548-3DAA77C1-6BB4-4801-BCA3-213339F0555B Q33744855-FC58CB55-3F89-440C-8F5F-92CDACAFC735 Q33769492-287A2BD6-1A53-46A5-B3E6-AE1656FCF9D3 Q33874365-E3E7E2E7-7D97-47C1-87D1-FF822C8CEF12 Q33896731-DD32E18B-C758-4E99-8E48-0046A1D3EE5F Q33936807-6FCCEBB5-2561-47AF-83AD-A969A27E063D Q33968921-E13CDA5B-4DAF-4418-83B0-4AC448B9BD36 Q34425077-6F58FA44-5249-4D97-9AE8-0325B3005EA5 Q34878637-95407710-5FD2-4924-B2D6-405080636854 Q35011149-B129731C-717B-4DE0-BF45-683A3083E2E5 Q35817322-2F85011C-BFE4-4077-966C-4F339AD0CE6F Q36014897-C2F20F3A-6E2C-4300-A461-B8B917484AEE Q36090448-FF7ACB14-B31F-4E4E-9274-3808FDDE4575 Q36113804-F3DF199B-3436-4D5A-B4EE-FAE8CF330B9B Q36608691-08F4DCA5-9086-4B88-B8B6-D292BD0EE370 Q36661722-C043CEF3-E730-4C90-9D23-0D0BE2CEDEAE Q36742811-F36C59B0-B35F-4B06-9FED-A3EB9C5BB410 Q36836697-7339C3FA-802D-48D7-B255-F3C308409CF4 Q37021288-9B5499FD-C12F-46A4-B3A6-3B11AB9CA270 Q37079820-58D4BC8C-6010-4873-AF09-BBDC788FC556 Q37149246-DDEE2EB5-FB0D-45D5-B1E1-7937F63D8B59 Q37182802-6D95D7C6-BBA0-424E-B75B-C99A2182F049 Q37188588-28F44383-CBBB-4CAD-B5BF-FA4D96116C9D

P2860

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

http://www.wikidata.org/entity/Q36930841

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

@en

type

label

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

@en

prefLabel

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

@en

P1433

Q36930841-B190ED46-5EE5-46D5-82F0-9E3BEE1FCF30

P1476

Q36930841-35C90424-A059-48FF-932F-171219C87B3D

P2093

Q36930841-2798E822-609C-4207-B0B0-FC6113D6BEE3

Q36930841-7AD2B7BF-964D-48AE-B048-5C89C8B6E032

Q36930841-A0CECBAF-46B1-40E2-8551-6677C9C2D56A

Q36930841-B6011E91-5A03-4ADC-8C5F-3FE5C02206F6

Q36930841-D06307F4-CFDB-4545-9E72-D38BAB5BC7D5

Q36930841-F1B8B244-A914-4E33-9F01-FF2F42F677CD

Q36930841-F2F55B53-C85C-42BD-8851-61B47EC92393

P2860

Q36930841-082160D6-7CE6-47A6-8CC4-FEB4BC05A338

Q36930841-0826C810-1D0F-43C5-A1A1-3E4DC2085B5A

Q36930841-09C15FFE-8DBD-4C01-BEE6-9732F2576164

Q36930841-110F4352-0DDC-4159-A7AE-502B1AC0ED87

Q36930841-2745D028-D196-4BAA-A117-02D21388466B

Q36930841-2B07A35B-ED55-495C-A30A-524AF3476460

Q36930841-2E30662D-6452-475E-AA63-F0BB6A9E9BF2

Q36930841-2E8A64DA-E4B4-4BD5-A10E-E42BF1A6DACA

Q36930841-3085E160-0B52-4E24-A5E0-3FC4B7C2C514

Q36930841-316699F8-9624-4344-80B7-961A78D804DA

P304

Q36930841-952E2D60-737F-407C-99FC-222D330E3D0E

P31

Q36930841-B08D64F9-AEE1-4970-B0FA-D95A11BAD730

P356

Q36930841-28905723-CBAD-4397-8D68-91514D3A59A3

P433

Q36930841-059C0F2A-4ED3-416C-9C40-902A0085F179

P478

Q36930841-C6FBB5E8-7334-44E6-9EBC-A50309109ECC

P50

Q36930841-E06DCF40-8340-4F74-B031-45EA99B00D61

P577

Q36930841-9443C9D1-355B-412E-A041-6B3E954FAFF6

P5875

Q36930841-70AAD8E8-4BB4-4D02-9D31-FECB58062710

P698

Q36930841-142EAA42-3A9D-4FB2-9258-B0A23EDA0CF6

P932

Q36930841-1B04CFCB-A2B5-4114-913D-6F6905F6CAB2

P356

J.CCR.2007.02.025

P1433

P1476

Synergy between PPARgamma ligands and platinum-based drugs in cancer.

@en

P2093

Elnaz Naseri

http://www.w3.org/2001/XMLSchema#string

Geoffrey D Girnun

http://www.w3.org/2001/XMLSchema#string

Jeffrey D Szwaya

http://www.w3.org/2001/XMLSchema#string

John A Alberta

http://www.w3.org/2001/XMLSchema#string

Lishu Qu

http://www.w3.org/2001/XMLSchema#string

Roderick Bronson

http://www.w3.org/2001/XMLSchema#string

Scott B Vafai

http://www.w3.org/2001/XMLSchema#string

P2860

PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis

PPAR gamma is required for the differentiation of adipose tissue in vivo and in vitro

Peroxisome proliferator-activated receptor gamma and cancers

Activation of transcription by two factors that bind promoter and enhancer sequences of the human metallothionein gene and SV40

Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma

APC-dependent suppression of colon carcinogenesis by PPARgamma

Expression and purification of the leucine zipper and DNA-binding domains of Fos and Jun: both Fos and Jun contact DNA directly

Hic-5 regulates an epithelial program mediated by PPARgamma

Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

P304

395-406

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCR.2007.02.025

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Bruce Spiegelman

P577

2007-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6349521

http://www.w3.org/2001/XMLSchema#string

P698

17482130

http://www.w3.org/2001/XMLSchema#string

P932

2564847

http://www.w3.org/2001/XMLSchema#string